LDL cholesterol still drives treatment decisions in assessing heart disease risk, but a new study suggests apolipoprotein B (apoB), which measures artery-clogging particles, could do a better job. In ...
ApoB is emerging as a crucial piece of the heart health puzzle, even as sophisticated machines whir and beep with promises of precise diagnoses in the gleaming corridors of modern medicine. As ...
The traditional lipid panel may not give the full picture of cholesterol-related heart disease risk for many Americans, according to a study led by UT Southwestern Medical Center researchers and ...
A new study shows apolipoprotein B (apoB) and non-high-density-lipoprotein (non-HDL) cholesterol — but not low-density-lipoprotein (LDL) cholesterol — are associated with increased risk for all-cause ...
People whose LDL cholesterol is in the normal range—even those without metabolic risk factors—may yet have levels of apolipoprotein B (apoB) that predict an elevated risk of future atherosclerotic ...
The risk of myocardial infarction in patients with and without atherosclerosis is best predicted by the number of apolipoprotein B (apoB)-containing lipoproteins, and this risk is independent from the ...
Share on Pinterest A new study suggests that not only is apoB testing effective for guiding cholesterol treatment, but also cost-effective. Image credit: aire images/Getty Images A study suggests that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results